| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02475369 Details | 2021-05-12 Interventional | 4 | 21 | Pancreatin Pancrelipase Celiac Disease | The trial was terminated prematurely by the sponsor for administrative reasons. Early termination by the sponsor leading to a small number of subjects analyzed. | |||
| NCT02097732 Details | 2021-05-12 Interventional | 2 | 4 | Ipilimumab Brain Neoplasms Melanoma Neoplasm Metast… Brain Metastase… Metastatic Mela… | Study halted prematurely due to a change in the standard of care treatment Study halted prematurely due to a change in the standard of care treatment. | |||
| NCT01562626 Details | 2021-05-12 Interventional | 1/2 | - | Flucytosine Cancer Neoplasms Tumors | - - | |||
| NCT03292653 2017-002774-39 Details | 2021-05-11 Interventional | 2 | 32 | (2S,3R,4R,5S,6R… Heart Failure Cardiac Failure… | 1st two cohorts provided the required data, therefore 3rd cohort was not deemed necessary - | |||
| NCT03673735 2018-002730-21 Details | 2021-05-10 Interventional | 3 | 0 | Durvalumab Carcinoma Squamous Cell H… | Company withdrew interest - | |||
| NCT03658213 Details | 2021-05-10 Interventional | 3 | 0 | Goserelin Breast Neoplasm… Breast Cancer | CTP of LARES has been out of the expire date, we are trying RWS pathway for the indication
expend - | |||
| NCT00809783 Details | 2021-05-10 Interventional | 3 | 2147 | Tanezumab Osteoarthritis | See termination reason in detailed description. Due to FDA imposed clinical hold, enrollment was stopped prematurely and, therefore, not all study procedures and visits occurred as planned. | |||
| NCT03844932 Details | 2021-05-07 Interventional | 2 | 235 | Cyclosporine Cyclosporins Colitis Colitis, Ulcera… Ulcer | The Sublimity Board of Directors carefully evaluated the IA data: the 9.6% treatment remission
difference for 75mg BID vs placebo (due to an increase in placebo response rate) was determined
not sufficient to continue to fund the study - | |||
| NCT04469062 2019-001653-99 Details | 2021-05-06 Interventional | 3 | 0 | Mirikizumab Vedolizumab Colitis Colitis, Ulcera… Ulcer Ulcerative Coli… | The trial was terminated secondary to a business decision, the original scientific question
rendered moot by the external scientific community. - | |||
| NCT04173611 Details | 2021-05-06 Interventional | 1 | 20 | Bupivacaine Healthy | Terminated for strategic and administrative reasons - | |||
| NCT02959437 Details | 2021-05-06 Interventional | 1/2 | 70 | Azacitidine INCB057643 Pembrolizumab Neoplasm Metast… Neoplasms Advanced Malign… Metastatic Canc… Solid Tumors | Study terminated by Sponsor - | |||
| NCT00003056 Details | 2021-05-06 Interventional | 3 | 105 | Cyclosporine Cyclosporins Methotrexate Graft vs Host D… Leukemia Lymphoma Graft Versus Ho… | Interim analysis indicated study should be terminated - | |||
| NCT01541670 Details | 2021-05-05 Interventional | 1 | 4 | Antibodies Lupus Erythemat… Lupus Nephritis Nephritis Systemic Lupus … | - - | |||
| NCT01089725 Details | 2021-05-05 Interventional | 3 | 385 | Tanezumab Osteoarthritis Arthritis Pain | See termination reason in detailed description. Due to United States Food and Drug Administration (FDA) imposed clinical hold, enrollment was stopped prematurely and, therefore, was insufficient to yield adequate power to fulfill the primary objectives. | |||
| NCT01126216 2005-003484-23 Details | 2021-05-04 Interventional | 3 | 221 | Cisplatin Paclitaxel Head and Neck N… Head and Neck C… | After an Interims analysis the Data Safety Monitoring board recommended this because no
significant difference between the two arms was seen and was not expected with an reasonable
recruitment of patients.
No interruptions of the trial were made. - | |||
| NCT04342221 2020-001224-33 Details | 2021-05-03 Interventional | 3 | 30 | Hydroxychloroqu… COVID-19 COVID-19, Hydro… | Reduced acceptance of IMP - | |||
| NCT03749590 2009-013294-18 Details | 2021-05-03 Interventional | 3 | 327 | Magnesium Sulfa… Pancreatitis Post-ERCP Pancr… | The design of the MagPEP trial is no longer in compliance with the current state of science. - | |||
| NCT02899702 Details | 2021-05-03 Interventional | 4 | 0 | Immunoglobulins… Communicable Di… Infections Shock Shock, Septic Staphylococcal … Streptococcal I… Staphylococcal … Streptococcal I… | no EC approval obtained - | |||
| NCT02860494 2018-002531-18 Details | 2021-05-03 Interventional | 2/3 | 0 | Everolimus Angiofibroma Sclerosis Tuberous Sclero… Facial Angiofib… | Pharmaceutical and financial difficulties - | |||
| NCT03376854 Details | 2021-04-30 Interventional | 2 | 0 | Neuromuscular B… Acute Lung Inju… COVID-19 Hypothermia Respiratory Dis… Respiratory Dis… Respiratory Dis… Sars-CoV2 | Competition from other studies and initiation of a larger multi center trial - |